Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors

MUMBAI, February 15, 2013 /PRNewswire/ --

Bharatbook.com is pleased to announce a new research report on Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors (http://www.bharatbook.com/healthcare-market-research-reports/drivers-of-m-a-in-2013-2016-pi3ks-and-btk-inhibitors.html)

New targets/drugs remain an evergreen medical need to address the unmet need of drug resistance in the treatment of cancer. Large global pharma are constantly on the hunt for drugs with label expansion potential = Longevity and Blockbuster Potential! About $10b+ has already been invested in licensing /acquisition of PI3K and other kinase inhibitors/companies since the last five years. Scientific data on the role of PI3K, BTK kinase in cancer and clinical Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a critical mass and companies with focus in this sector are poised to offer better treatment options for unmet need in hematologic malignancies. We expect more acquisitions of the innovator companies and or handsome licensing deals for unpartnered products as mature data and approvals come in the next few years. This report highlights the recent progress on the understanding of PI3Ks/BTK signaling pathway and companies developing PI3K/BTK inhibitors, the clinical data and competition.

     (Logo: http://photos.prnewswire.com/prnh/20130128/590935 )

Key Points Discussed in the Report

  • Drugs in the pipeline

PI3K inhibitors - Infinity pharma (INFI), Gilead (GILD)

Dual PI3K inhibitor - Onconova/SymBio, Curis (CRIS)

BTK-inhibitors - Safety and clinical efficacy set it apart - Pharmacyclics (PCYC), Celgene (CELG)

  • M&A in Kinase Inhibitors in the last 5 years
  • Related Milestones/catalysts in 2013-14
  • Combination Studies - PI3K, BTK inhibitors with Rituxan, Bendamustine in hematological cancers.
  • Ongoing Clinical Trials of Companies Covered
  • Detailed reports on

SymBio pharma (4582, ¥488)

Curis (CRIS, $2.99)

Gilead (GILD, $40.36)

Pharmacyclics (PCYC, $69.28) -

Infinity pharma (INFI, $35.02)

Request for Sample pages - http://www.bharatbook.com/RequestSample.asp?pid=372901

Table of Contents

Executive Summary

Drugs in the Pipeline

Phosphoinositide 3-Kinases (PI3Ks) inhibitors

Scientific Rationale

Dual inhibitors

Bruton's Tyrosin Kinase (BTK) Inhibitors

Scientific Rationale

BTK inhibitors - Pipeline

M&A to Follow - Kinase inhibitors have attracted partnering deals at a premium

Kinase Inhibitor: Select M&A / Deals

Upcoming Milestones Related in 2013-14

Combination Studies - PI3K, BTK + Rituxan/ Bendamustine

Idelalisib (GS-1101) - Clinical Data

Rigosertib - Clinical Data

Other PI3K or Dual Inhibitors - Clinical Data

Combination Studies of PI3K and BTK Inhibitors

Ongoing Trials of PI3K and BTK Compounds

Company Analysis

Curis (CRIS) -

Gilead -

Infinity Pharma

Pharmacyclics

SymBio

Get an overview of the report at or request for sample pages at -

http://www.bharatbook.com/healthcare-market-research-reports/drivers-of-m-a-in-2013-2016-pi3ks-and-btk-inhibitors.html

For Complete range of Related Reports:

About Bharat Book Bureau

Bharat Book Bureau is the leading market research information aggregator that provides market research reports, industry analysis, company profiles, business reports, country reports, newsletters and online databases. Our clients include Corporate, Consulting firms, and Academic Institutions and Government departments across the globe. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. The market research reports we provide, help global companies examine the different markets before setting up a business or expanding into different countries across the world. They give a complete perspective on the current market scenario, trends, segments and future outlook.

Contact us:
Maria
Bharat Book Bureau
India: +91-22-27810772, 27810773
USA/Canada - 1-866-279-8368 (Toll free)
Skype - bharatbook
E-mail: maria@bharatbook.com
Website: http://www.bharatbook.com

SOURCE Bharat Book Bureau



More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.